4 completed, 4 not yet recruiting, 2 recruiting, 2 terminated. 8 Phase 1, 6 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Not yet recruiting 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 6 | Not yet recruiting 2, Terminated 2, Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Peripheral T-cell Lymphoma (PTCL): new trials by email Literature Review of Peripheral T-cell Lymphoma (PTCL) trials Research Report on Peripheral T-cell Lymphoma (PTCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma EBV TCR-T - NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 24 | 2025-09-20 | 2025-12-02 |
| A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma (PTCL) | Not yet recruiting | Ruijin Hospital | 1000 | 2025-04-30 | 2025-05-09 | |
| AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. AZD3470, Pembrolizumab - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 161 | 2024-01-23 | 2026-10-13 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors KT-333 - Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Completed | Kymera Therapeutics, Inc. | 56 | 2022-05-19 | 2025-03-19 |
| Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma Decitabine with GemOx, GemOx - Peripheral T-cell Lymphoma (PTCL) | Phase 2 | Terminated | Seoul National University Hospital | 17 | 2020-11-13 | 2025-04-24 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies L-Bcl-2 antisense oligonucleotide - Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Active not recruiting | Bio-Path Holdings, Inc. | 30 | 2020-11-05 | 2025-02-24 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
| Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) HBI-8000 - Peripheral T-Cell Lymphoma (PTCL) | Phase 2 | Completed | HUYABIO International, LLC. | 55 | 2016-11-01 | 2024-09-19 |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) Pralatrexate Injection - Peripheral T-Cell Lymphoma (PTCL) | Phase 1 | Completed | Acrotech Biopharma Inc. | 48 | 2015-11-10 | 2021-07-27 |
| Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma Selinexor - Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | Terminated | Karyopharm Therapeutics Inc | 16 | 2015-02-01 | 2023-01-26 |
Lymphoma, T-Cell, Peripheral (13) · Lymphoma, T-Cell, Cutaneous (5) · Hodgkin Disease (3) · Leukemia, Large Granular Lymphocytic (2) · Leukemia, Prolymphocytic, T-Cell (2) · Lymphoma, Non-Hodgkin (2) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoma, T-Cell (13) · Lymphoproliferative Disorders (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Lymphoma (12) · Lymphoma, Non-Hodgkin (11) · Hematologic Diseases (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Leukemia, T-Cell (3) · Disease Attributes (2)
Decitabine (2) · selinexor (2) · 10-propargyl-10-deazaaminopterin (1) · Alemtuzumab (1) · Azacitidine (1) · HBI-8000 (1) · Interleukin-15 (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · pembrolizumab (1)
Ruijin Hospital (2) · Acrotech Biopharma Inc. (1) · AstraZeneca (1) · Bio-Path Holdings, Inc. (1) · HUYABIO International, LLC. (1) · Karyopharm Therapeutics Inc (1) · Kymera Therapeutics, Inc. (1) · Medsyn Biopharma, LLC (1) · National Cancer Institute (NCI) (1) · Seoul National University Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · The Methodist Hospital Research Institute (1)
United States (6) · China (3) · South Korea (3) · Australia (2) · Japan (2) · Brazil (1) · France (1) · Germany (1) · Italy (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Ashwin Gollerkeri, MD (1) · Erard Gilles, MD (1) · Gloria Lee, MD (1) · Helen Heslop, MD (1) · Kevin Conlon, M.D. (1) · Krish Patel, MD (1) · Premal Lulla, MD (1)
PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28911074, PMID 29920566, PMID 32508818, PMID 33242451, PMID 33883258, PMID 35475910, PMID 36200417, PMID 37781191, PMID 38029357
2023 (1)